Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008

SAN DIEGO, March 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2007 financial results after the close of market on Wednesday, March 12, 2008.

Cadence management will host a conference call and live webcast to discuss the financial results and provide a corporate overview on Wednesday, March 12, 2008 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 877-681-3375 (domestic) or 719-325-4913 (international). To access the webcast, please visit the company's website at http://www.cadencepharm.com/ and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, including intravenous acetaminophen (IV acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com/.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue
SVP & Chief Financial Officer
Cadence Pharmaceuticals, Inc.
858-436-1400

Anna Gralinska
Director, Investor Relations
Cadence Pharmaceuticals, Inc.
858-436-1452

First Call Analyst:
FCMN Contact: shogan@cadencepharm.com

Source: Cadence Pharmaceuticals, Inc.

CONTACT: William R. LaRue, SVP & Chief Financial Officer,
+1-858-436-1400, or Anna Gralinska, Director, Investor Relations,
+1-858-436-1452, both of Cadence Pharmaceuticals, Inc.

Web site: http://www.cadencepharm.com/

2008-03-06 20:51:41 0306947 PRNEWSWIRE